Butyrate of sodium – effective partner in therapy Review article

Main Article Content

Maciej Kierzkiewicz

Abstract

Butyric acid is an organic chemical compound belonging to the carboxylic acids group. It usually arises from the breakdown of butter and is supplied to the body via food (especially in milk and its products, silage) and is naturally produced in the body by bacteria living in the large intestine, e.g. Bacillus by fermentation of undigested carbohydrates and hexose oligomers. Butyric acid and its esters (butyrate) have antioxidant properties and are consumed in physiological processes by intestinal epithelial cells (enterocytes) for energy production. Numerous studies confirm the health-promoting effect of butyrates (improvement of intestinal microbiome, enterocytes nutrition, regeneration of the reconstructive properties and integrity of the intestinal epithelium, reduction of cytokine and chemokine secretion, as well as alleviation of abdominal pain), which justifies their use in therapy of various gastrointestinal tract diseases.


The effectiveness and safety of butyrates has been proven in, among others, irritable bowel syndrome, pouchitis (after partial intestinal resections), intestinal disorders following antibiotic therapy, diverticular colon disease (diverticulosis) or food allergies.

Article Details

How to Cite
Kierzkiewicz, M. (2018). Butyrate of sodium – effective partner in therapy. Medycyna Faktow (J EBM), 11(1(38), 19-22. https://doi.org/10.24292/01.MF.0118.3
Section
Articles

References

1. Polskie Towarzystwo Farmaceutyczne: Farmakopea Polska X. Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Warszawa 2014: 4276.
2. Mrzigod J., Nowakowski J. (red.): Podręczny słownik chemiczny. Videograf II, Katowice 2004: 212.
3. Banasiewicz T., Borycka-Kiciak K., Dobrowolska-Zachwieja A. et al.: Kliniczne aspekty zastosowania kwasu masłowego w postępowaniu dietetycznym w chorobach jelit. Prz. Gastroenterol. 2010; 5(6): 329-334.
4. Kotunia A., Pietrzak P., Guilloteau P., Zabielski R.: Kwas masłowy w przewodzie pokarmowym. Prz. Gastroenterol. 2010; 5(3): 117-122.
5. Tarnowski W., Borycka-Kiciak K., Kiciak A. et al.: Wyniki leczenia zespołu jelita nadwrażliwego z zastosowaniem kwasu masłowego – raport wstępny. Gastroenterol. Prakt. 2011; 1: 43-48.
6. Canani R.B., Costanzo M.D., Leone L. et al.: Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J. Gastroenterol. 2011; 17(12): 1519-1528.
7. Roediger W.E.: The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980; 2(8197): 712-715.
8. Hamer H.M., Jonkers D., Venema K. et al.: Review article: the role of butyrate on colonic function. Aliment. Pharmacol. Ther. 2008; 27(2): 104-119.
9. Gao Z., Yin J., Zhang J. et al.: Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58(7): 1509-1517.

Most read articles by the same author(s)